Estimation of Trometamol content in Gadobutrol solution for intravenous administration by using RP-LC with Refractive Index DetectorV-Reference-Cited by-同舟云学术

Estimation of Trometamol content in Gadobutrol solution for intravenous administration by using RP-LC with Refractive Index DetectorV

Published:2022-12-24 Issue: Volume: Page:5597-5602
ISSN:0974-360X
Container-title:Research Journal of Pharmacy and Technology
language:en
Short-container-title:RJPT

Author:

Babu Najana Sanni¹,Babu Bollikolla Hari¹

Affiliation:

1. Department of Chemistry, Acharya Nagarjuna University, Nagarjunanagar, Guntur, Andhra Pradesh, India.

Abstract

Extremely responsive technique designed for the willpower of trometamol for instance tris(hydroxymethyl) aminomethane in gadobutrol by RP-LC technique. Quantification of trometamol content in gadobutrol samples by HPLC with refractive index detector (RID). Trometamol was UV inactive compound. Trometamol was determined by RP-LC method using Inertsil NH2 (250x4.6mm, 5µm) column as motionless segment. Column temperature maintained 30°C, inoculation quantity 10µL, flow velocity was 0.3 ml/min, sample cooler temperature 25°C. The mixture of phosphate buffer and cyanomethane in the ratio of 990:10 (volume/volume) was utilized as movable segment. The technique legalization erstwhile conceded as indicated by ICH guidelines.

Publisher

A and V Publications

Subject

Pharmacology (medical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Reference23 articles.

1. Product information for Aus PAR Gadovist Gadobutrol Bayer Australia Ltd PM-2013-04968-1-2 Final 1 June 2015.

2. Cheng KT "Gadobutrol" (PDF). Molecular Imaging and Contrast Agent Database (MICAD). National Center for Biotechnology Information (NCBI), 2007.

3. "Bayer in Radiology–Gadavist® (gadobutrol) injection 1 mol/mL". bayerimaging.com. Retrieved 20 May 2015.

4. "FDA approves imaging agent for central nervous system scans"(Press release). U.S. Food and Drug Administration (FDA). March 15, 2011. Retrieved March 31, 2011.

5. "U.S. FDA Approves Bayer's Gadavist (Gadobutrol) Injection for MRI of the Central Nervous System" (Press release). Bayer HealthCare Pharmaceuticals. March 14, 2011. Archived from the original on May 2, 2011. Retrieved March 31, 2011.